Physician profile
Monique Tolston
NPI 1750395109
$3,594.76
in general payments reported to CMS, 2019-2025
29 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,546 · 2022: $1,206 · 2023: $498 · 2024: $224 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.15 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $403.29 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $300.43 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $257.06 | 2021-2023 | Xarelto |
| Amgen INC. | $251.57 | 2021-2023 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $230.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $166.92 | 2021-2023 | |
| Glaxosmithkline, LLC. | $166.39 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $117.85 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $101.66 | 2021-2022 | |
| Esperion Therapeutics, INC. | $83.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.59 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.64 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $60.40 | 2025 | Nexplanon |
| Exact Sciences Corporation | $55.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.30 | 2022 | |
| Global Blood Therapeutics, INC. | $52.79 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $44.07 | 2022-2023 | Farxiga |
| Renalytix Ai, INC. | $40.20 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Eisai INC. | $34.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.49 | 2021 | |
| Astellas Pharma US INC | $23.24 | 2023 | Myrbetriq |
| Amarin Pharma, INC. | $20.04 | 2021 | |
| Evofem Biosciences, INC. | $18.17 | 2022 | |
| Phadia US INC. | $17.40 | 2021 | |
| Clarus Therapeutics INC. | $15.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Tolston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.